Experience of application of combined treatment patients with chronic non-spectacular prostate with using polycomponent medicine and alpha adrenoblockatоrs
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: was to analyze the clinical efficacy of the complex treatment of men with chronic prostatitis (CP) using the drugs Pravenor® in capsules and Omiks at 0.4 mg.
Materials and methods. Outpatients were 77 men with chronic nonspecific prostatitis, which is accompanied by symptoms of the lower urinary tract. The age of patients ranged from 22 to 36 years, the duration of the disease – from 8 months to 4 years. All 77 patients with CP completed the full course of complex treatment with the use of drugs Pravenor® in capsules and Omiks at 0.4 mg. The duration of treatment was 90 days.
Results. As a result of the complex treatment of men with CP with the use of drugs Pravenor® and Omiks, the condition of the patients quickly improved. The use of therapy provided a fairly rapid clinical effect. Painful sensations were eliminated after completion of the course of treatment in 26 (92.9%) of 28 subjects, dysuric phenomena were eliminated in 72 (93.5%) of 77 patients.
Conclusion. The use of drugs Pravenor® and Omix in men with chronic prostatitis (CP) is clinically justified. The efficiency was 93.5%. The use of drugs Pravenor® and Omix in men with CP was accompanied by good tolerability and a small number of side effects (5.2%). The results obtained make it possible to recommend the use of the drug Pravenor® and alpha-blocker Omix for complex treatment of CP.##plugins.themes.bootstrap3.article.details##
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Сексологія і андрологія / Під ред. акад. О.Ф. Возіанова та проф. І.І. Горпинченка // Вид. «Здоров’я». – К., 1996.
Проскура О.В. Неспецифические простатиты и везикулиты: Руководство по клинической урологии / Под ред. А.Я. Пытеля. – М., 1970. – С. 193–208.
Тиктинский О.Л. Воспалительные неспецифические заболевания мочеполовых органов. – Ленинград. – 1984.
Простатит (П.А. Щеплев и др.). – М.: ИД МЕДПРАКТИКА-М, 2005. – 224 с.
Lubasch A., Keller I., Borner K. Koeppe P., Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000:44: 2600–3. https://www.doi.org/10.1128/AAC.44.10.2600-2603.2000
Ильин И.И. Негонококковые уретриты у мужчин., 2-е изд. перераб. и доп. – М.: Медицина, 1993. – 256 с.
Мавров И.И., Бухарович В.Г., Глухенький Б.Т. и др. Контактные инфекции, передающиеся половым путем / Пoд ред. И.И. Маврова. – К.: Здоровья, 1989. – 230 с.
Скрипкин Ю.К., Шарапова Г.Я., Селисский Г.Д. Болезни, передающиеся при половых контактах. – Медицина, 1985. – 284 с.
Meares E.M. Urethritis, Prostatitis, Epididimitis and Orchitis. // lnfections diseases / Eds. S.L. Gorbadi, G. Bartlett, N.K. Blacklow. – W.B. Saunders Co., 1992.
Drach G.W., Meares E.M., Fair W.R., Stamey T.A. Classification of benign diseases associated with prostatic pain: Prostatitis or prostatodynia //J. Urology. – 1978. – Vol. 120. – P. 266. https://doi.org/10.1016/S0022-5347(17)57135-9
Meares E.M. Dysuria and perineum pain in males: Prostatitis syndroma. // Difficult diagnoses in urology. Eds. // D.L. McCollough. – Churchill Co. – 1988.
Nickel J.С. Prostatitis: Myths and realities // Urology. – 1998. – Vol. 51. – P. 362–366. https://doi.org/10.1016/S0090-4295(97)00643-2
Resveratrol and Endothelial Nitric Oxide Ning Xia, Ulrich Förstermann and Huige Li. Molecules 2014, 19, 16102-16121; https://doi.org/10.3390/molecules191016102
The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1 Br J Cancer. 2002 Mar 4; 86(5): 774–778. https://doi.org/10.1038/sj.bjc.6600197